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PURPOSE: Although a potential role of the Epstein-Barr virus (EBV) in the pathogenesis of breast cancer (BC) has been underlined,
results remain conflicting. Particularly, the impact of EBV infection on biological markers of BC has received little investigation.
METHODS: In this study, we established the frequency of EBV-infected BC using real-time quantitative PCR (RT–PCR) in 196 BC
specimens. Biological and pathological characteristics according to EBV status were evaluated.
RESULTS: EBV DNA was present in 65 of the 196 (33.2%) cases studied. EBV-positive BCs tended to be tumours with a more
aggressive phenotype, more frequently oestrogen receptor negative (P¼0.05) and with high histological grade (P¼0.01).
Overexpression of thymidine kinase activity was higher in EBV-infected BC (P¼0.007). The presence of EBV was weakly associated
with HER2 gene amplification (P¼0.08).
CONCLUSION: Our study provides evidence for EBV-associated BC undergoing distinct carcinogenic processes, with more aggressive
features.
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A viral aetiology is one recently evocated theory behind the
physiopathology of breast cancer (BC) (Glaser et al, 2004;
de Villiers et al, 2005; zur Hausen, 2009). Even though, the
mechanistic aspects of cancer induction by infectious agents sound
multiples, that is, immunosuppressive, linked to animal–human
transmission, direct or indirect oncogenic, there are epidemiolo-
gical evidences of pathogens involvement in human cancer (zur
Hausen, 2009).
Among the putative viruses observed in BC tissue, the presence
of the Epstein-Barr virus (EBV), a g-herpes virus, has been
reported in a number of studies (Bonnet et al, 1999; Fina et al,
2001; Glaser et al, 2004). The implication of EBV in carcinogenesis
associated with other cancers, such as Burkitt’s lymphoma,
undifferentiated nasopharyngeal carcinoma, as well as Hodgkin’s
disease, has been well documented (zur Hausen, 1991).
However, the presence and implication of EBV in BC remains
controversial. The use of conventional technical approaches
(in situ hybridisation, immunochemistry and standard PCR)
for its detection may explain the conflicting results. Some groups
have failed to detect EBV (Chang et al, 1992; Gaffey et al, 1993;
Lespagnard et al, 1995; Chu et al, 1998; Glaser et al, 1998;
Dadmanesh et al, 2001; Deshpande et al, 2002; Herrmann and
Niedobitek, 2003; Perrigoue et al, 2005), whereas results from
others show discrepancy and depended on the methodology used.
For instance, although Murray et al (2003)could detect EBV
nuclear antigen-1 by immunochemistry using 2B4-1 monoclonal
antibody, they failed to detect the EBV genome by quantitative
PCR. The reasons behind these apparently conflicting results
remain to be clarified; however, technical limitations of the assays,
dissimilarities in the archival materials and heterogeneity among
cluster cells contaminated by the EBV genome may be same.
Moreover, EBV positivity has been linked to the presence of
latently infected lymphocytes in the tumours (Horiuchi et al, 1994;
Brink et al, 2000) thus, questioning the role of EBV in BC (Chu
et al, 2001). However, in accordance with other groups (Labrecque
et al, 1995; Luqmani and Shousha, 1995; Bonnet et al, 1999; Chu et al,
2001; Huang et al, 2003; Preciado et al, 2005; Arbach et al,2 0 0 6 ;
Perkins et al,2 0 0 6 ;T s a iet al,2 0 0 7 ) ,w eh a v es h o w nt h ep r e s e n c eo f
EBV genetic information in a subset of BC tissue with a specific
localisation in the epithelial malignant cells (Fina et al, 2001).
Currently, real-time PCR (RT–PCR is increasingly being used
for both research and clinical applications. For BC in particular,
the detection of HER2 gene amplification has been validated by
comparison with conventional methods, such as FISH (Lamy et al,
2006). Analysis using RT–PCR might also help to clearly identify
the presence of EBV in BC. However, the use of whole tissue can
result in the risk of contamination and this risk has been corrected
with the introduction of laser-assisted microdissection (Fina et al,
2001). In studies on formalin-fixed sections, micro- and macro-
dissected breast tumours have been tested for the presence of
multiple regions of the EBV genome with few actually uncovering
the viral sequence (McCall et al, 2001; Thorne et al, 2005).
Interestingly, by in situ hybridisation using a (35)S-labelled
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sriboprobe for Epstein-Barr encoded RNA 1 and a laser capture
microdissection on frozen samples, combined with quantitative
PCR (Q-PCR), we showed that EBV localisation was restricted
to certain tumour epithelial cell clusters (Fina et al, 2001).
In accordance with our findings, Arbach et al (2006) observed
that viral load is variable between tumours and is heterogeneously
distributed among morphologically identical tumour cells, some
clusters containing high genome numbers compared with others
negative for EBV genome within the same specimen.
In the present study, we hypothesised that EBV-infected BC cells
might behave differently in comparison to those negative for EBV.
In order to test this, we sought to (i) measure the frequency of EBV
positivity using RT–PCR and (ii) to compare the biological
phenotype of EBV-negative and EBV-positive tumours.
MATERIALS AND METHODS
Patients
This study involved 196 primary invasive breast carcinomas, with
clinical and pathological characteristics as outlined in Table 1.
Patients were consecutively recruited in Marseille France, between
May 1996 and December 1998. Tumours were graded according
to the Scarff Bloom and Richardson classification (Bloom and
Richardson, 1957). Axillary lymph node status was assessed by
histological examination. The local Medical Ethics Committee
(IRB) approved this laboratory study on stored specimens.
Tissue specimens All tumour samples were histologically exam-
ined by a pathologist at the time of initial surgery and stored
in liquid nitrogen. Frozen tissue (100mg) was pulverised with a
micro-dismembrator and the frozen powder subsequently used for
DNA extraction (Sambrook et al, 1982). Cytosols were prepared
using a Tris buffer (10mM Tris-HCl, 1.5mM EDTA, 10mM
Na2MoO4, 0.5mM dithiothreitol, 10% glycerol, pH 7.4).
Q-PCR analysis All Q-PCR reactions were performed on an ABI
Prism 7700 sequence detection apparatus (Perkin-Elmer Corp.,
Foster City, CA, USA). The 50-exonuclease (TaqMan) assay was
used. Measurements were performed in duplicates. Levels of HER2
expression were normalised to those of the somatostatin receptor
type II gene SSTR2 localised on chromosome 17 (q24) and to the
glyceraldehyde-3-phosphate dehydrogenase gene GAPDH localised
on chromosome 12 (p13). Levels of the BamHIC sub-region of the
EBV genome were also normalised to GAPDH. After normalisation
to GAPDH, the between-run CVs for BamHIC and HER2 internal
controls (four series) were less than 10%.
Q-PCR analysis of HER2 gene
The Q-PCR reaction conditions used have already been published
(Lamy et al, 2006). The calibration curve was prepared from
normal human genomic DNA (Roche Molecular Biochemicals,
Meylan, France). Data were expressed as the HER2/GAPDH and
HER2/SSTR2 relative copy number ratio. The human SKBR3 and
A431 cell lines, known to, respectively, display HER2 amplification
or not, were used as controls.
Q-PCR analysis of the EBV genome
The Q-PCR analysis of the EBV genome was performed as
previously described (Fina et al, 2001). Briefly, primers for
BamHIC were: sense, 50-AAA-CAG-GAC-AGC-CGT-TGC-C-30
(6935–6953); antisense, 50-AAG-CCT-CTC-TTC-TCC-TTC-CCC-30
(7036–7016) and the probe was 50-FAM-TTT-CGG-ACA-CAC-
CGC-CAA-CGC-T-TAMRA-30 (6961–6983). The cycling condi-
tions for both BamHICs were as follows: 951C for 15min; 45 cycles
of 941C for 20s, and 551C for 20s. Amplification was performed in
a 50-ml reaction volume with a buffer consisting of 10mmoll
–1
Tris-HCl (pH 8.3; 251C), 50mmoll
–1 KCl, 10mmoll
–1 ethylene-
diamine tetraacetate and 5mmoll
–1 MgCl2 in the presence of
200mmoll
–1 deoxy(d)-ATP, dCTP and dGTP, 400mmoll
–1 dUTP,
200nmoll
–1 of each primer, 200nmoll
–1 probe, 1U Amp Erase
UNG (Perkin-Elmer Corp.), and 1.25U AmpliTaq Gold polymerase
(Perkin-Elmer Corp.). To quantify the EBV genome load in the
tissues, genomic DNA prepared from the Raji cell line, containing
50 integrated EBV copies per cell was used. Serial dilutions of DNA
were prepared from 1ng to 0.1pg equivalent to 15000–1.5 copies
of EBV genome, respectively. Absolute quantification of the
BamHIC standard curve involved comparison against normal
human genomic DNA (Roche Molecular Biochemicals). The
calibration curve for GAPDH was directly prepared from normal
human genomic DNA. BamHIC data were expressed as the number
of BamHIC copies per 100ng GAPDH. Normal human genomic
DNA and controls lacking DNA always remained negative in the
BamHIC Q-PCR analyses.
Biochemical assays Oestrogen receptors and progesterone recep-
tors (PRs) (EIA, Abbott Laboratories, Chicago, IL, USA), as well as
Table 1 Frequency of EBV positivity according to patient and tumour
characteristics
Characteristics n
EBV+ (%)
(n¼65)
EBV  (%)
(n¼131) P-value
All 196 33.2 66.8
Age (years)
o50 54 17 (31.5) 37 (68.5) NS
X50 142 34 (33.8) 63 (66.2)
Tumour size (pT)
o2cm 99 31 (31.3) 68 (68.7) NS
42cm 97 34 (35.0) 63 (65.0)
Nodal status (pN)
N  120 30.0 70.0 NS
N+ 76 38.2 61.8
Histological grade
I 37 6 (16.2) 31 (83.8) 0.01
II 103 33 (32.0) 70 (68.0)
III 56 26 (46.4) 30 (53.6)
ER
Negative 44 20 (45.4) 107 (54.6) 0.05
Positive 152 45 (29.6) 45 (70.4)
PR
Negative 62 23 (37.1) 39 (62.9) NS
Positive 134 42 (31.3) 92 (68.7)
UPA
Low 147 14 (34.7) 35 (65.3) NS
High 49 51 (28.6) 96 (71.4)
PAI-1
Low 147 48 (32.6) 99 (67.4) NS
High 49 17 (34.7) 32 (65.3)
TK
Low 147 24 (27.9) 25 (72.1) 0.007
High 49 41 (49.0) 106 (51.0)
HER2 amplification 14 16 0.13
Abbreviations: %  ,%+ ¼percentage of tumours negative and positive for
EBV, respectively; EBV¼Epstein-Barr virus; ER¼oestrogen receptor; NS¼not
significant; PAI-1¼plasminogen activator inhibitor 1; PR¼progesterone receptor;
TK¼thymidine kinase; UPA¼urokinase plasminogen activator.
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inhibitor type 1 (PAI-1) (UPA Imubind no 894 and PAI-1
Immubind no 821, both from American Diagnostica, Greenwich,
CT, USA) were measured with enzyme immunoassays. Thymidine
kinase (TK) activity was determined by a radioenzymatic
phosphorylation assay (TK-REA, Sangtec Medical, Bromma,
Sweden) optimised to detect the fetal TK1 isoenzyme, as previously
described (Romain et al, 1994). Quality control was assured by
frequent testing with internal controls. The EORTC standards were
also used for oestrogen receptor and PR (Geurts-Moespot et al,
2000).
Statistical analysis Associations between categorical variables
were tested by the w
2-test. Relationships between categorical and
continuous variables were examined using the Mann–Whitney
test, or in the case of more than two ordered categories, by the
Kruskal-Wallis test. A P-value of o0.05 was considered significant.
The HER2 gene was considered amplified when the HER2/GAPDH
relative copy number was X2.0. A threshold value of 4.0 was used
to define a strong HER2 amplification. Samples with receptor
content X20fmolmg
–1 protein were classified as oestrogen
receptor or PR positive. Cut-offs corresponding to the seventy-
fifth percentiles in the distributions were used to dichotomise
UPA, PAI-1 (Bouchet et al, 1999) and TK (Romain et al, 1995,
2000, 2001) as previously recommended.
RESULTS
Patient characteristics
The demographics of the studied patients are reported in Table 1.
The tumours had a diameter of more than 2cm in 97 patients
(49.5%). In all, 76 patients (38.8%) had positive axillary lymph
nodes. The histological differentiation was determined as grade 3
in 56 tumours (28.6%).
HER2 gene amplification was detected in 15.3% (n¼30) of the
analysed BCs, with the HER2/GAPDH ratio for amplified cases
ranging from 2.0–22.1 (median 4.5). Among the HER2-amplified
tumours, 43.3% (n¼13) showed moderate HER2 amplification
(HER2/GAPDH ratio 2.0–4.0) and 56.7% (n¼17) a strong
amplification (HER2/GAPDH ratioX4.0).
Q-PCR analysis of the EBV genome
To ensure that the presence of EBV was related to epithelial cells,
as previously described (Fina et al, 2001). Tissue sections were
microdissected with a PixCell II LCM system (Arcturus Engineering,
Mountain View, CA, USA). For each tumour analysed, several
epithelial areas (approximatively 5 10
3 cells) were independently
captured; stromal areas without infiltrating malignant epithelial
cells were pooled to provide a sufficient number of GAPDH copies.
Cell populations were estimated to be homogeneous as determined
by microscopic visualisation. DNA from laser-captured cells was
extracted and subsequently used for Q-PCR.
The presence of the BamHIC sub-region of the EBV genome was
used to define EBV positivity. EBV was detected in 65 (33.2%) of
the 196 investigated BCs. Among the positive tumours, the load of
EBV genome varied from 0.08 to 810.8 BamHIC copies per 100ng
GAPDH (median 1.4). Fibrocystic diseases (n¼3), fibroadenomas
(n¼6), phyllode tumours (n¼4) and normal mammary tissue
obtained from mammoplasty (n¼2) were also analysed. They
were all found to be negative, with the exception of one phyllode
tumour (0.43 BamHIC copies per 100ng GAPDH).
Detection of the EBV genome and patient characteristics
Table 1 shows the frequency of the EBV genome according to the
characteristics of the patient and tumour.
Tumour positive for EBV presented markers of proliferation.
Thus, the proportion of EBV-positive samples was significantly
higher among the high-grade tumours (16.2% for grade I, 32.0%
for grade II and 46.4% for grade III, P¼0.01). EBV-positive
samples were more frequent among those of ER-negative (45.4%)
compared with ER-positive tumours (29.6%) (P¼0.05). Among
the tumours with high TK, 49.0% displayed the EBV genome
compared with 27.9% of those with low TK (P¼0.007). In contrast,
no significant link was observed between the detection of the EBV
genome and age at diagnosis, tumour size, lymph node involve-
ment, PR, UPA or PAI-1 status.
To quantitatively assess the relation between the EBV presence
and pathological markers, we have studied the load of EBV
genome. We confirmed that BamHIC copy numbers were higher
among high-grade tumours (P¼0.006) and between those
ER-negative (P¼0.01) and high TK value (P¼0.009). Other
relationships were not significant (Table 2).
Detection of the EBV genome and amplification of HER2
A weak association was observed between EBV genome presence
and HER2 amplification. Subgroups with EBV– HER2– (n¼115)
Table 2 Mean EBV load (BamHIC copies) according to biological
characteristics
Characteristics
Mean EBV load
(BamHIC copies per
100ng GAPDH) P-value
Age (years)
o50 0.79 0.42
X50 7.84
Tumour size (pT)
o2cm 1.28 0.70
X2cm 10.60
Nodal status (pN)
N  1.40 0.34
N+ 13
Histological grade
I 0.32 0.006
II 2.58
III 15.7
ER
Negative 1.64 0.01
Positive 20.58
PR
Negative 1.83 0.20
Positive 14.67
UPA
Low 7.48 0.56
High 1.12
PAI-1
Low 7.21 0.75
High 1.93
TK
Low 1.87 0.009
High 17.95
No HER2 amplification 27.9 0.10
HER2 amplification 1.9
Abbreviations: ER¼oestrogen receptor; PAI-1¼plasminogen activator inhibitor 1;
PR¼progesterone receptor; TK¼thymidine kinase; UPA¼urokinase plasminogen
activator.
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sand EBVþ HER2þ (n¼14) status represented 65.8% of the
investigated patients (P¼0.09). When using the Mann–Whitney
test, EBV-positive tumours showed the highest HER2 copy
numbers though the difference did not reach significance
(P¼0.08).
DISCUSSION
The aim of this study was to investigate the presence of EBV in BC,
alongside possible associations with clinicopathological factors
and biological tumour features that either mark the natural history
of the disease or determine the therapeutic outcome. The analysed
biological factors were selected on the basis of their high utility
score in the tumour marker grading system (Isaacs et al, 2001),
with evidence coming either from prospective trials or meta-
analysis (ER, PR, HER2, UPA and PAI-1), or at least from large
retrospective studies (TK).
The implication of EBV in the aetiology of BC has been
addressed in other series, including a multicentric study carried
out by our group (Fina et al, 2001). In accordance with tour
analysis, the presence of EBV was showed to be restricted in the
epithelial cells (Fawzy et al, 2008; Trabelsi et al, 2008; Joshi et al,
2009). EBV has been evocated along with other viruses, such as the
papillomavirus (de Villiers et al, 2005; Kulka et al, 2008) or
polyomavirus (Berebbi et al, 1990), as well as cytomegalovirus
(Richardson et al, 2004). One of the controversies surrounding
EBV as a causal agent in BC has been its potential coincidental
presence as no virus-related physiopathological effects have
emerged from pathological observations. However, one interesting
epidemiological study provided some arguments in favour of a role
and a potential explanation relating to the stage of mammary gland
development. Indeed Yasui et al (2001) showed a correlation
between the incidence of infectious mononucleosis and the risk of
BC. Particularly, an increase in age corresponding to a later stage
of mammary gland development at infectious mononucleosis onset
seemed to increase the risk for BC. We have also observed this
potential link between the incidence of BC and hormonal status in
one of our previous studies with the polyomavirus (Berebbi et al,
1990). Our evaluation of oncogenicity in nude mice showed that
mammary tumour induction was oestrogen-dependent during a
short period after polyomavirus injection. This sensitivity of the
mammary gland to virus exposure corresponds to an oestradiol-
mediated modification of the target organ occurring during ductal
development (Berebbi et al, 1990). After this developmental
period, the mitogenic stimulus induced by hormones is no longer
necessary. The influence of hormonal environment during the
critical period of mammary gland development thus determines
the future carcinogenesis process and the pool of hormone-
responsive epithelial cells (Nandi et al, 1995). However, the
analysis of changes in EBV immunoglobulins (Ig) showed
discrepant results; thus, although Cox et al (2010) failed to
show an association with the risk of BC in Ig taken before and
after the development of BC, in contrast Joshi et al (2009)
observed no difference that mean anti-EBNA-1 IgG levels were
significantly higher in BC patients as compared with benign breast
disease.
The Q-PCR method has been used here to investigate EBV in a
large series of BCs. Overall, 33.2% of the 196 frozen tumours
analysed contained the BamHIC sub-region of the EBV genome
that encodes the Epstein-Barr encoded RNAs. In our previous
multi-centre study (Fina et al, 2001), the samples from our centre
showed a positive ratio of 26.7% by standard PCR. The higher
percentage of EBV-positive tumours observed in the present study
may be related to the size of the tumours samples analysed,
(100mg), and to the sensitivity of Q-PCR. Two other investigators
have also found EBV by PCR in frozen tissues by PCR (Labrecque
et al, 1995; Bonnet et al, 1999). The absence of detection
(Gaffey et al, 1993; Lespagnard et al, 1995) or the low detection
rate even by RT–PCR (McCall et al, 2001) that has elsewhere been
reported elsewhere could be due to result from the use of fixed
tissues. Indeed, it has been demonstrated that fixation generates
both PCR-inhibitory components (Satoh et al, 1998; Ko ¨sel et al,
2001; kalkan et al, 2005) and sequence alterations (Williams et al,
1999; Amarante and Watanabe, 2009). Inhibition of the viral DNA
PCR amplification was most likely the case for the study of McCall
and colleagues (McCall et al, 2001). Kalkan et al (2005) and Thorne
et al (2005) detected EBV genome in epithelial and also in normal
cells. In these studies, low amounts of template DNA was probably
used as the tissues were microdissected and DNA amplificability
was controlled by HER2 detection. In our BC samples, the loads
of EBV genetic information (BamHIC per 100ng DNA) ranged far
below the range of HER2 values (HER2/GAPDH copy number).
The high heterogeneity in EBV detection that has been
shown within individual tumours also needs to be considered
(Fina et al, 2001).
In this study, we observed a difference in clinical and biological
profiles between EBV-positive and EBV-negative cancers.
In accordance with Tsai et al (2007) though in contrast toMurray
et al (2003), we found no correlation between the presence of EBV
and nodal status. Here, we have investigated markers of epithelial
cells (ER, PR, grade and TK), whereas UPA and PAI-1, which
are markers of stromal-epithelial interactions, associated with
tumoural invasion process. In line with this result, no association
was observed with the biological factors (UPA or PAI-1) related to
tumour invasion. However, we did confirm that the proportion
of EBV-positive samples is higher among the high-grade and the
ER-negative cancers (Bonnet et al, 1999; Murray et al, 2003). These
latter biological factors related to differentiation status (Rose et al,
1985; McGuire et al, 1986; Murray et al, 2003) were strongly
associated with EBNA-1 as detected by immunostaining. Alto-
gether these results confirm the epithelial presence of EBV as only
correlations with epithelial markers were observed and not with
the markers of stromal compartment. Interestingly, we showed a
positive association between the presence of EBV and high
cytosolic TK enzyme activity. High expression of this enzyme
involved in the DNA synthesis salvage pathway has previously
been associated with large tumour size, high histological grade and
steroid hormone receptor negativity (Romain et al, 2000). The TK
encoded by the EBV is localised in the centrosome, a localisation
observed in diverse cell types whether the protein is expressed
independently or in the context of lytic EBV infection (Gill et al,
2007). Although EBV TK is an early gene, it was nevertheless found
to be transcribed with a significant delay compared with other
early-class RNAs (Yuan et al, 2006). The commercial assay used to
access TK activity has been optimised for the TK1 isoenzyme. The
link between EBV and TK supports the notion that EBV is
associated with fast-growing tumours. It agrees with data
suggesting that DNA tumour viruses suppress the transcriptional
downregulation of TK activity during the eukaryotic cell cycle
(Hengstschla ¨ger et al, 1994), and that nasopharyngeal carcinomas
with detectable EBV LMP1 protein grow faster than the non-
expressing ones (Hu et al, 1995). Concerning the link between EBV
positive tumours and high TK expression, we sequenced mRNA
and found that the expression of TK gene found in EBV-positive
tumours is of human origin, not viral (data not shown).
This human TK differs from the one deposited by Bradshaw
and Deininger in the Genbank database (Gilles et al, 2003).
In a previous study, Huang et al (2003), detected the EBV-encoded
lytic transactivator protein ZTA in 7 out of 10 BCs. Interes-
tingly, ZTA specifically binds the CCAAT motif (C/EBPa,
enhancer binding protein a) of the TK1 human gene promoter,
which suggests a functional role in the activation of TK1
transcription.
In this study, the presence of EBV was only weakly associated
with HER2 amplification. This result, together with the fact that
Epstein-Barr virus in breast cancer
C Mazouni et al
335
British Journal of Cancer (2011) 104(2), 332–337 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sEBV and HER2 correlate differently with other tumour
features, suggests that the viral infection and the gene amplifica-
tion occur at different times during BC progression. In BCs,
both EBV (Bonnet et al, 1999) and HER2 (Re ´villion et al, 1998;
Yamauchi et al, 2001) have been associated with a lack of
oestrogen receptors.
In conclusion, we confirmed the presence of EBV in one third of
BC. Moreover, EBV-positive tumours presented with a more
aggressive phenotype that could be useful when considering
potential therapeutic targets. In particular, the high TK levels could
confer resistance to chemotherapy.
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